Recently I read this book and found it very insightful and interesting. This book is highly underrated because of no advertisement. The intention for the writing this book by Mr Pulak Prasad is not to earn profit from selling it.
This book is about adopting a new mindset for investing-about reimagining investing by applying the time tested principles of biological evolution. Mr. Pulak Prasad told that the more he studied Darwinian evolution the more he learned about investing. This book is for long term investors and for readers with eclectic taste who are looking for something interesting to read.
I rate it 10/10.
Posts tagged Value Pickr
Multi-Disciplinary Reading – Book Reviews (29-06-2024)
Sanghvi Movers (29-06-2024)
Assuming the same NPM will remain in rental business the net profit from 600 Cr would be 600×0.3= 180 Cr and NP on EPC 400 Cr× 0.12 = 48 Cr
Total net profit in fy25 = 228 Cr. Thats 20 PE on fy25 earnings. Ignoring Capex.
I think people got injected OPM vaccine and developed a fixation around it.
Journey and Portfolio of a goal-based NEEV investor (29-06-2024)
Portfolio update (June 2024):
Update: Used 4th June market crash to deploy ~4% of cash in the existing portfolio (which gave >10% gain so far - luck has many names); namely TIPS LTD, IRCTC, COAL INDIA, VARUN BEV, NARAYANA and WONDERLA.
Also, 100% exited PHANTOM VFX (with minor tuition fees) position since the expected triggers did not pan out. New challenges from Gen AI continue to create difficulties in perception (although reality might be different). Also, the company’s corp governance wrt of disclosure looked lackadaisical (ref: June 1, 2024). Also “receivables” crept up to Rs 51 cr in FY24 from Rs 16 cr in FY23. The risk/reward of holding a micro-cap stock without growth triggers, corp gov challenges and unfavourable financials (receivables) doesn’t look favourable at this point. Hopefully, the learnings of this industry will help in the future.
Again, I feel there are very few opportunities for me right now. Hence, shoring up cash once again and spending more time expanding my circle of competence.
Although studying the paper Industry (have learnings from SATIA), co-working space, wealth management and few opportunities in spaces wrt premiumization trend.
Here’s my latest portfolio:
Stock name | Weight | Avg P/E | Current P/L % | Total P/L % | IRR % | Action |
---|---|---|---|---|---|---|
MOST 100 ETF | 8.8% | 17.9 | 66% | 68% | 32.9 | |
BANK BEES ETF | 7.1% | 12.0 | 42% | 42% | 21.6 | |
TATA INVEST CORP | 6.9% | 24.6 | 246% | 250% | 142.5 | |
TIPS LIMITED | 6.8% | 20.4 | 102% | 122% | 56.8 | Added more |
BAJAJ FINANCE | 6.7% | 22.2 | 36% | 42% | 13.0 | |
IRCTC | 6.7% | 29.0 | 145% | 189% | 53.5 | Added more |
DIXON | 6.4% | 42.1 | 355% | 601% | 101.6 | |
COAL INDIA | 6.4% | 4.7 | 68% | 74% | 91.4 | Added more |
TITAN | 6.3% | 46.7 | 85% | 101% | 23.6 | |
VARUN BEVERAGES | 5.2% | 53.9 | 82% | 83% | 64.8 | Added more |
PIDILITE | 4.4% | 56.6 | 64% | 78% | 19.2 | |
AMARA RAJA * | 4.0% | 10.1 | 145% | 146% | 190.4 | |
INDIAMART | 3.9% | 44.8 | 9% | 51% | 32.2 | |
NARAYANA HEALTH | 3.9% | 24.1 | 29% | 29% | 32.3 | Added more |
ASIAN PAINTS | 3.8% | 46.1 | 9% | 25% | 8.0 | |
CASH | 3.8% | - | - | - | ||
IEX | 3.2% | 14.7 | 213% | 166% | 22.5 | |
TATA ELXSI | 3.0% | 34.2 | 61% | 156% | 50.1 | |
WONDERLA * | 2.7% | 31.5 | 4% | 4% | 15.3 | Added more |
*(asterisk) signifies <1 yr holding period.
Here’s the return profile till June 2024:
TRI till June 2024 | 1M | 3M | 6M | 1Y | 3Y | 5Y | Since inception |
---|---|---|---|---|---|---|---|
MY PORTFOLIO | 4.9% | 7.7% | 14.0% | 39.8% | 14.5% | 23.8% | 22.3% |
NIFTY 50 | 4.5% | 8.2% | 10.6% | 27.0% | 14.7% | 15.4% | 15.0% |
NIFTY 500 | 4.7% | 11.9% | 16.5% | 38.9% | 18.4% | 18.7% | 16.3% |
Note: 1/3/6M is in absolutes while the 1/3/5Y/SI is annualized. The inception date is 10th Nov 2016.
Disclaimer: I am neither a financial nor a SEBI registered advisor. The content shared here is only for learning purposes. So please use your discretion to make any buy/sell decision and not use the above as a recommendation.
Ambika Cotton Mills (29-06-2024)
Hi- None can predict cotton price as it is a global commodity which depends on many factors out of anyone’s control like rainfall, acreage, availability of quality seeds etc… I found it very uncomfortable Ambika management blocking so much money on inventory… Cotton prices rose after covid for which Ambika got benefit and I am reasonably sure that Ambika mngt also didn’t predict it ( If they have predicted cotton price rise, they would have stocked up taking loans as their balance sheet is debt free) . So when they couldn’t predict cotton price movement in the past, I should reasonably assume that Ambika may not successfully predict even now and hence they may lose if cotton price falls…If they are lucky enough, cotton price rises and they pocket the benefit of rise on the cotton stock…… And when Ambika mngt with decades of experience couldn’t predict cotton prices, I don’t think outsiders like us can predict its movements with certainty……current facts are cotton seed producers like kaveri mentioned that seed stocks are low… but at the same time, cotton yarn/ fabric exports are under severe pressure as consumers in western markets are reeling under financial stress owing to high inflation etc and hence their discretionary spends are affected… so quite difficult to make a prediction with certainity reg cotton price…
Screener.in: The destination for Intelligent Screening & Reporting in India (29-06-2024)
Hi @kowshick_kk and Screener team, just posting here for visibility as I have already shared with the team but I’m hoping this can be implemented on priority.
Need additional data for ‘3 quarters back’. (corresponding previous quarter of upcoming quarter)
Currently - Sales, Operating Profit & Net Profit are available.
Here are the parameters needed:
- Other income 3 quarters back
- Extraordinary Income 3 quarters back
- Profit before Tax 3 quarters back
I need it for the upcoming earnings season so that data can be compared Year on Year.
The same data is available for the ‘preceding year quarter’ like this:
I have been requesting this since a couple of quarters now and while I do understand it is more data you have to show, but it is data that is already available and just needs to be accessible to users.
Hoping for a quick resolution!
Tata Steel – Would be merger be of any value? (29-06-2024)
This information is little off topic however, just wanted to share my understanding and things that is happening with TATA Steel.
After Tata Steel UK initiated legal action against an employee’s union after their announcement on early shutdown of its operations at the Port Talbot facility. This all started when Tata steel planned to shut down its loss-making business by decommissioning two blast furnaces and replace it with Electric Arc furnace project. The Company had also sought support from the UK Government and came to an agreement to invest £500 million.
Now what’s the issue?
Around 2800 jobs will be lost in closure of the blast furnaces. Also, the long-term Steel making sustainability would come to a pause.
Hence, Employee union’s secretary Sharon Graham stated that “We call on the real decision makers in Mumbai to take hold of this dispute, sit down, negotiate, and realise that the investment secured will be good for the company and workers.”
What the Company is doing?
The Company has urged the Union to withdraw its strike that is going to start from July 8, 2024 and consider its proposal which includes “generous” employee support packages, training, and skills development.
In the coming days, if the Company is unable to continue to safely and stably operate the assets through the period of strike action, they will have to pause or stop heavy-end operations (including both blast furnaces) on the Port Talbot site.
The Company has emphasized that shutting down operations would be extremely costly and disruptive throughout the supply chain.
They also stated that safety of people on the site will be their priority.
To Conclude, Tata Steel being one of the largest steel manufacturing Company around the globe, these disruptions would not hamper the long-term goals of the Company. However, if the operations are being paused or stopped for a longer duration it would badly affect the company’s topline growth in the near term.
Do share your thoughts on above information.
Multi-Disciplinary Reading – Book Reviews (29-06-2024)
But these funds performance avialable since 2007 only post 2008 crisis Central banks printed so much monies which expaned PE ratio to unsustainable level for QUALITY companies
Wockhardt: an NiCE story (29-06-2024)
Excerpt from Chairman’s Speech at AGM, convened on June 28, 2024, at 11 am
- Over a span of 25 years, we dedicated substantial efforts to establish a global antibiotic research organisation.
- Fostered a culture of Research and Innovation, collaborating with more than 30 global organisations.
- Invested over US$ 500 million in discovering antibiotics to address unmet medical needs.
- Our diverse antibiotic portfolio tackles antimicrobial resistance across various classes, developed over 30-40 years, targeting infections in both hospital and community settings.
EMROK & EMROK O
- EMROK & EMROK O have treated more than 65,000 patients.
- Successfully concluded 4 new clinical studies covering bloodstream infections, bone and joint infections, community-acquired bacterial pneumonia, and infections in immunosuppressed patients.
- Completed New Drug Application (NDA) submissions in 10 Emerging Markets countries and aiming for 5-6 additional countries by Q2 of FY 2025.
- Anticipating substantial growth in the current year due to these expansions.
WCK 4873 (Nafithromycin), trademarked as MIQNAF
- MIQNAF (WCK 4873) offers an ultrashort, 3-day oral treatment for community-acquired bacterial pneumonia, achieving a 97% success rate.
- Current treatments face up to 60% resistance.
- Filed New Drug Application (NDA) with the Drug Controller General of India (DGCI) and anticipate commercial launch in India by the second half of FY25.
- Planning NDA filings in selected Emerging Markets and foreseeing strong sales in FY26.
WCK 5222 (Zidebactam/Cefepime), trademarked as ZAYNICH
- A groundbreaking new antibiotic developed by Wockhardt.
- This proprietary drug, designed to combat major superbugs, is the first of its kind discovered in the past 50 years.
- Currently in Global Phase 3 clinical trials.
- ZAYNICH was granted compassionate use approval by the DCGI for 30 critically ill patients unresponsive to existing antibiotics.
- Achieving a 100% success rate, ZAYNICH saved the lives of all recipients, with notable cases published in prestigious international journals.
- To date, ZAYNICH has saved over 30 lives, with DCGI approval secured for a small-scale clinical trial involving carbapenem-resistant patients in India.
- Pending completion by FY25, approval would enable ZAYNICH to become available in India, marking a significant milestone in its clinical deployment.
- The US FDA granted ‘Expanded Access IND’ approval for WCK 5222 (ZAYNICH) to treat a young cancer patient at the University of California Irvine School of Medicine, Orange County.
- Despite nine months of unresponsiveness to current US antibiotics, the patient showed significant improvement within four weeks of ZAYNICH administration.
- The treatment resulted in complete healing of large wounds and eradication of infections, allowing the patient to resume chemotherapy for ongoing cancer treatment.
- CLSI, a globally-recognized US body, has approved a susceptibility breakpoint of 64 mg/L for ZAYNICH.
- This breakpoint applies to a wide spectrum of Gram-negative pathogens resistant to multiple drugs.
- ZAYNICH demonstrates unprecedented effectiveness with its high bacteria kill power, crucial for extreme multi-drug resistant organisms.
- For the first time, a breakpoint of 64 mg/L covers the entire spectrum of 10-resistant Gram-negative pathogens, underscoring ZAYNICH’s clinical potency.
- Clinical trials under compassionate use show a 100% success rate in critically ill patients, affirming its safety and efficacy over 70 days.
- ZAYNICH’s achievement of the investigational breakpoint at a CLSI plenary session on June 24, 2024, marks a historic milestone, a source of pride for Wockhardt and India.
- Global Phase III clinical trials for ZAYNICH are anticipated to conclude by FY25.
- Plans include filing for regulatory approvals in the US, Europe, and other regions following trial completion.
- Global approval for ZAYNICH’s launch worldwide is expected in FY26.
- Strategically, we aim to maximize market value through a dual strategy: direct marketing in India and Emerging Markets, alongside licensing agreements with global pharmaceutical companies for US, Europe, and other developed regions.
Source: https://www.wockhardt.com/wp-content/uploads/2024/06/chairmans-agm-speech-2024.pdf
Garware Hi-Tech Films Ltd: A Hidden Consumer Story in the Polyester Film Industry (29-06-2024)
The speciality films portfolio mainly comprises Sun control films, shrink films, paint protection films and low oligomer products. The share of value-add products of the Company has increased from 48%
of overall revenues in FY17 to 80% as of FY23.
To support Garware Application Studios, we have launched a product, Titanium, which is top of the top rolls, but only given to GAS.
XPEL their competitor - has signaled headwinds but to that question management said they already did well for thei Qtr vs XPEL